Xenon Pharmaceuticals (XENE) Shares Outstanding (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Shares Outstanding (Entity) of $96.6 million for Q1 2026, up 26.16% year-over-year from $76.6 million in Q1 2025, and up 20.76% quarter-over-quarter from $80.0 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Shares Outstanding (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Shares Outstanding (Entity) for 14 consecutive years, with $96.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 26.16% year-over-year to $96.6 million; the TTM figure through Mar 2026 stood at $96.6 million (up 26.16% YoY), while the FY2025 annual figure was $80.0 million, up 4.7% from the prior year.
- Shares Outstanding (Entity) climbed to $96.6 million in Q1 2026 per XENE's latest filing, from $80.0 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $96.6 million in Q1 2026 and bottomed at $53.1 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $71.7 million across 5 years, with a median of $75.5 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 51.38% — and 2024, when it grew 1.39%.
- Xenon Pharmaceuticals' Shares Outstanding (Entity) stood at $62.6 million in 2022, then rose by 20.42% to $75.4 million in 2023, then grew by 1.39% to $76.4 million in 2024, then advanced by 4.7% to $80.0 million in 2025, then grew by 20.76% to $96.6 million in 2026.
- Business Quant data shows XENE's Shares Outstanding (Entity) at $96.6 million in Q1 2026, $80.0 million in Q4 2025, and $77.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 99.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.61 Mn |
| Mar 31, 2026 | 87.35 Mn |
| Dec 31, 2025 | 79.25 Mn |
| Sep 30, 2025 | 79.25 Mn |
| Jun 30, 2025 | 78.95 Mn |
| Mar 31, 2025 | 78.69 Mn |
| Dec 31, 2024 | 77.89 Mn |
| Sep 30, 2024 | 77.93 Mn |
| Jun 30, 2024 | 77.67 Mn |
| Mar 31, 2024 | 77.59 Mn |
| Dec 31, 2023 | 66.89 Mn |
| Sep 30, 2023 | 66.00 Mn |
| Jun 30, 2023 | 65.86 Mn |
| Mar 31, 2023 | 65.72 Mn |
| Dec 31, 2022 | 60.54 Mn |
| Sep 30, 2022 | 65.47 Mn |
| Jun 30, 2022 | 56.19 Mn |
| Mar 31, 2022 | 54.85 Mn |
| Dec 31, 2021 | 43.63 Mn |
| Sep 30, 2021 | 41.19 Mn |